Search Result
Results for "
cardiac function
" in MedChemExpress (MCE) Product Catalog:
10
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-109128
-
|
MYK-491
|
Myosin
|
Cancer
|
|
Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency .
|
-
-
- HY-103137
-
|
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Zacopride hydrochloride is an orally active 5-HT3 receptor (Ki of 0.38 nM) antagonist and 5-HT4 receptor (Ki of 373 nM) agonist. Zacopride hydrochloride exhibits multiple activities, such as regulating gastrointestinal motility, affecting cardiac function, and exerting anxiolytic and antiemetic effects. Zacopride hydrochloride is currently mainly used in the research of gastrointestinal diseases, cardiovascular diseases, and psychiatric diseases such as anxiety .
|
-
-
- HY-147384
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
CXL-1020 is a hydroxylamine-based nitroxyl (HNO) donor. CXL-1020 improves cardiac inotropy/lusitropy and Ca 2+ cycling in rats with abnormal relaxation. CXL-1020 induces vasorelaxation and improves cardiac function in canine models. CXL-1020 has been used to research systolic heart failure and stable heart failure .
|
-
-
- HY-176716
-
|
|
Aldehyde Dehydrogenase (ALDH)
|
Cardiovascular Disease
|
|
ALDH2 activator 1 (Compound Z17) is an allosteric aldehyde dehydrogenase 2 (ALDH2) agonist. ALDH2 activator 1 enhances cardiac function and reduces myocardial necrosis in a mouse model of myocardial ischemia-reperfusion. ALDH2 activator 1 is promising for research of cardiovascular diseases such as myocardial infarction (MI) .
|
-
-
- HY-124051
-
|
|
Elastase
|
Cardiovascular Disease
Inflammation/Immunology
|
|
BAY-8040 is a pyrimidopyridazine derivative which has inhibitory activity against human neutrophil elastase (HNE). BAY-8040 decreases cardiac remodeling and ameliorates cardiac function in a Monocrotaline (HY-N0750)-induced rat model for pulmonary arterial hypertension. BAY-8040 is promising for research of inflammatory pathologies and cardiopulmonary pathologies .
|
-
-
- HY-126401
-
|
IQB-875 free base
|
Calcium Channel
|
Cardiovascular Disease
|
|
Elgodipine (IQB-875 free base) is an orally active dihydropyridine calcium antagonist and an antianginal compound. Elgodipine inhibits both T- and L-type calcium channels (IC50: 32 and 2.3 nM). Elgodipine lowers systemic vascular resistance and improves systolic cardiac function .
|
-
-
- HY-118317
-
|
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Zacopride is an orally active 5-HT3 receptor (Ki of 0.38 nM) antagonist and 5-HT4 receptor (Ki of 373 nM) agonist. Zacopride exhibits multiple activities, such as regulating gastrointestinal motility, affecting cardiac function, and exerting anxiolytic and antiemetic effects. Zacopride is currently mainly used in the research of gastrointestinal diseases, cardiovascular diseases, and psychiatric diseases such as anxiety .
|
-
-
- HY-162897
-
|
|
mAChR
|
Cardiovascular Disease
|
|
BAY-2413555 is an orally active muscarinic acetylcholine receptor M2 modulator that protects the heart and improve cardiac function. BAY-2413555 is promising for research of heart failure .
|
-
-
- HY-145285
-
|
|
Apelin Receptor (APJ)
|
Cardiovascular Disease
|
|
APJ receptor agonist 5 (compound 3) is a potent and orally active agonist of apelin receptor (APJ) with an EC50 of 0.4 nM. APJ receptor agonist 5 displays excellent pharmacokinetic profiles in the rodent heart failure (HF) model. APJ receptor agonist 5 also shows an acceptable safety profile in preclinical toxicology studies. APJ receptor agonist 5 leads to improved cardiac function and can be used for researching the HF disease .
|
-
-
- HY-P1271
-
|
Catestatin (cattle)
|
nAChR
|
Cardiovascular Disease
|
|
Catestatin is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin is an endogenous peptide that regulates cardiac function and blood pressure . Catestatin is a non-competitive nicotinic antagonist acting through nicotinic acetylcholine receptors (nAChRs) to inhibit catecholamine release .
|
-
-
- HY-16121
-
|
|
Cathepsin
|
Others
|
|
CAA-0225 is a tissue protease L inhibitor that inhibits rat liver tissue protease L with a IC50 value of 1.9 nM. CAA-0225 can participate in the degradation of autophagosome membrane markers LC3-II and GABARAP (HY-P72639), improve cardiac function in mice with reperfusion injury, and kill and eliminate Trypanosoma brucei parasites [1][2][3].
|
-
-
- HY-P1271A
-
|
|
nAChR
|
Cardiovascular Disease
|
|
Catestatin TFA is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin TFA is an endogenous peptide that regulates cardiac function and blood pressure . Catestatin TFA is a non-competitive nicotinic antagonist acting through nicotinic acetylcholine receptors (nAChRs) to inhibit catecholamine release .
|
-
-
- HY-106486A
-
|
|
Others
|
Others
|
|
Butoprozine hydrochloride functions as a cardiac depressant agent.
|
-
-
- HY-147292
-
|
CK-136
|
Calcium Channel
|
Cardiovascular Disease
|
|
Nelutroctiv (CK-136) is an orally active and selective cardiac troponin activator. Nelutroctiv activates cardiac sarcomeres by enhancing the sensitivity of troponin to calcium ions and promoting the interaction between actin and myosin. Nelutroctiv enhances cardiac contractility. Nelutroctiv can be used in the researches for cardiovascular diseases with impaired cardiac contractile function .
|
-
-
- HY-103137R
-
|
|
Reference Standards
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Zacopride (hydrochloride) (Standard) is the analytical standard of Zacopride (hydrochloride). This product is intended for research and analytical applications. Zacopride hydrochloride is a highly potent 5-HT3 receptor antagonist with Kis of 0.38 and 373 nM for 5-HT3 and 5-HT4 receptor, respectively. Zacopride hydrochloride is also a moderate IK1 channel agonist. Zacopride hydrochloride exerts significant antiarrhythmic and cardiac protective effects .
|
-
-
- HY-106844A
-
|
|
Others
|
Cardiovascular Disease
|
|
(+)-EMD 57033 is a cardiac troponin C (cTnC) activator, is a dominant Ca 2+ sensitizer. (+)-EMD 57033 binds the cardiac/slow skeletal troponin C isoform and exerts myocardial contractile promotion function .
|
-
-
- HY-106530
-
|
AC 2770; Formiloxin; Formiloxine
|
Others
|
Others
|
|
Gitoformate (AC 2770) is a semisynthetic cardiac glycoside. Gitoformate can be used for renal function research .
|
-
-
- HY-B1409
-
|
ISDN
|
NO Synthase
|
Cardiovascular Disease
|
|
Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI) .
|
-
-
- HY-50910
-
|
CCI-779
|
mTOR
Autophagy
Apoptosis
Bacterial
|
Cancer
|
|
Temsirolimus is an inhibitor of mTOR with an IC50 of 1.76 μM. Temsirolimus activates autophagy and prevents deterioration of cardiac function in animal model .
|
-
-
- HY-111475
-
|
|
Mitochondrial Metabolism
|
Cardiovascular Disease
|
|
Mitochondrial fusion promoter M1 is a mitochondrial dynamic modulator. Mitochondrial fusion promoter M1 preserves the mitochondrial function and promotes cellular respiration. Mitochondrial fusion promoter M1 alleviates cardiac and brain damage in rats with cardiac ischemia/reperfusion injury .
|
-
-
- HY-109128S
-
|
MYK-491-d6
|
Isotope-Labeled Compounds
Myosin
|
Cardiovascular Disease
|
|
Danicamtiv-d6 (MYK-491-d6) is a deuterated labeled Danicamtiv (HY-109128). Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency .
|
-
-
- HY-109128S1
-
|
MYK-491-d3
|
Isotope-Labeled Compounds
Myosin
|
Cardiovascular Disease
|
|
Danicamtiv-d3 (MYK-491-d3) is a deuterated labeled Danicamtiv (HY-109128). Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency .
|
-
-
- HY-P10336
-
|
|
Serpin
|
Neurological Disease
Endocrinology
|
|
Serpinin is an agonist of the protease inhibitor Nexin-1 (PN-1). Serpinin upregulates the expression of PN-1 through the cAMP-PKA-Sp1 signaling pathway, promoting granule biogenesis in endocrine cells. Serpinin is used in research related to the regulation of secretory function . Serpinin is a selective agonist for β-adrenergic receptors. Serpinin interacts with β1-adrenergic receptors to activate the AC-cAMP-PKA pathway, which regulates myocardial systolic and diastolic function. pGlu-serpinin upregulates Bcl2 mRNA transcription and exerts neuroprotective effects .
|
-
-
- HY-P1373
-
|
|
Somatostatin Receptor
|
Neurological Disease
|
|
Neuronostatin-13 human is a 13-amino acid peptide hormone encoded by the somatostatin gene and plays an important role in the regulation of hormonal and cardiac function.
|
-
-
- HY-19121
-
-
-
- HY-109128S2
-
|
MYK-491-d3-1
|
Isotope-Labeled Compounds
Myosin
|
Cardiovascular Disease
|
|
Danicamtiv-d3-1 (MYK-491-d3-1) is a deuterated labeled Danicamtiv (HY-109128). Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency .
|
-
-
- HY-N7709
-
|
|
Others
|
Cardiovascular Disease
|
|
Cinchonain IIb is a proanthocyanidin. Cinchonain IIb has the effect of rational utilization of decreased cardiac function. Cinchonain IIb is isolated from natural hawthorn (Crataegus spp. ) .
|
-
-
- HY-P1428A
-
|
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
|
|
RFRP-1(human) TFA is a potent endogenous NPFF receptor agonist (EC50 values are 0.0011 and 29 nM for NPFF2 and NPFF1, respectively). Attenuates contractile function of isolated rat and rabbit cardiac myocytes. Reduces heart rate, stroke volume, ejection fraction and cardiac output, and increases plasma prolactin levels in rats.
|
-
-
- HY-157655
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Cafedrine-theodrenaline can stimulate the cardiovascular system through β-adrenergic receptor mediation, increasing arterial pressure, stroke volume, and cardiac output, while reducing peripheral vascular resistance, thereby supporting overall cardiac function. Cafedrine-theodrenaline helps maintain blood pressure during hypotensive episodes without causing significant tachycardia .
|
-
-
- HY-121259
-
|
Adriamycinol; DXR-OL
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Doxorubicinol, a potent inhibitor of the cardiac sarcoplasmic reticulum calcium pump, inhibits systolic myocardial function in isolated heart muscle. Doxorubicinol inhibits tumor cell growth and has cardiotoxicity.
|
-
-
- HY-103193
-
|
Colforsin dapropate hydrochloride
|
Adenylate Cyclase
|
Cardiovascular Disease
|
|
NKH477 (Colforsin dapropate hydrochloride) directly activates the catalytic unit of adenylate cyclase and increases intracellular cAMP. NKH477 is a forskolin derivative that improves cardiac failure mainly through its beneficial effects on diastolic cardiac function. NKH477 exerts an antiproliferative effect in vivo with an altered cytokine profile to inhibit the acute rejection of rat orthotopic lung allografts .
|
-
-
- HY-112205
-
RR-11a
2 Publications Verification
|
Legumain
|
Cancer
|
|
RR-11a is a synthetic enzyme inhibitor of Legumain (IC50=31-55 nM). RR-11a can be used for the research of cancer and acute myocardial infarction (AMI) .
|
-
-
- HY-17629R
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
Cancer
|
|
Dapansutrile (Standard) is the analytical standard of Dapansutrile. This product is intended for research and analytical applications. Dapansutrile is a potent, orally active and selective NLRP3 inflammasome inhibitor. Dapansutrile has anti-inflammatory activity and decreases immune factor levels. Dapansutrile can be used for research of inflammatory diseases .
|
-
-
- HY-17629
-
|
OLT1177
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
Cancer
|
|
Dapansutrile is a potent, orally active and selective NLRP3 inflammasome inhibitor. Dapansutrile has anti-inflammatory activity and decreases immune factor levels. Dapansutrile can be used for research of inflammatory diseases .
|
-
-
- HY-18347
-
|
YM 087 free base
|
Vasopressin Receptor
|
Cardiovascular Disease
|
|
Conivaptan (YM 087 free base) is antagonist for vasopressin V1A receptor and vasopressin V2 receptor. Conivaptan ameliorates congestive heart failure, improves cardiac systolic function .
|
-
-
- HY-176041
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
Troponin modulator 1 (compound 7) modulates the mutant cardiac muscle thin filament function. Troponin modulator 1 enhances Ca 2+ sensitivity by phosphorylation with an EC50 of 67 μM .
|
-
-
- HY-B1409S
-
|
ISDN-13C6
|
NO Synthase
|
Cardiovascular Disease
|
|
Isosorbide dinitrate- 13C6 is the 13C labeled Isosorbide dinitrate . Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI) .
|
-
-
- HY-50910R
-
|
|
mTOR
Autophagy
Apoptosis
Bacterial
|
Cancer
|
|
Temsirolimus (Standard) is the analytical standard of Temsirolimus. This product is intended for research and analytical applications. Temsirolimus is an inhibitor of mTOR with an IC50 of 1.76 μM. Temsirolimus activates autophagy and prevents deterioration of cardiac function in animal model .
|
-
-
- HY-B1409R
-
|
ISDN (Standard)
|
Reference Standards
NO Synthase
|
Cardiovascular Disease
|
|
Isosorbide dinitrate (Standard) is the analytical standard of Isosorbide dinitrate. This product is intended for research and analytical applications. Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI) .
|
-
-
- HY-D0711
-
|
Foxgreen; IC Green; Cardiogreen
|
Fluorescent Dye
|
Cancer
|
|
Indocyanine green (Foxgreen) is a low toxicic fluorescent agent that has been widely used in medical diagnostics, such as determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography (Ex/Em = 785/813 nm) .
|
-
-
- HY-B0124A
-
|
AD 810 sodium; CI 912 sodium
|
Carbonic Anhydrase
Apoptosis
|
Cardiovascular Disease
Neurological Disease
|
|
Zonisamide (AD 810) sodium is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide sodium exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide sodium also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide sodium can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
|
-
-
- HY-B0124
-
|
AD 810; CI 912
|
Carbonic Anhydrase
Apoptosis
|
Neurological Disease
|
|
Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
|
-
-
- HY-174671
-
|
|
mRNA
|
Cardiovascular Disease
|
|
Human HBEGF mRNA encodes the human heparin binding EGF like growth factor (HBEGF) protein, a growth factor that mediates its effects via EGFR, ERBB2 and ERBB4. HBEGF may be involved in normal cardiac valve formation and normal heart function.
|
-
-
- HY-B0124R
-
|
AD 810 (Standard); CI 912 (Standard)
|
Reference Standards
Carbonic Anhydrase
Apoptosis
|
Neurological Disease
|
|
Zonisamide (Standard) is the analytical standard of Zonisamide. This product is intended for research and analytical applications. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
|
-
-
- HY-B0124S2
-
|
AD 810-13C6; CI 912-13C6
|
Isotope-Labeled Compounds
Carbonic Anhydrase
Apoptosis
|
Neurological Disease
|
|
Zonisamide- 13C6 (AD 810- 13C6) is 13C labeled Zonisamide. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
|
-
-
- HY-N6020B
-
|
|
Others
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Butin is a major biologically active flavonoid isolated from the heartwood of Dalbergia odorifera with oral activity, with strong antioxidant, antiplatelet and anti-inflammatory activities. Butin significantly alleviates myocardial infarction and improves heart function, together with prevents diabetes-induced cardiac oxidative damage in rat .
|
-
-
- HY-D0711R
-
|
|
Fluorescent Dye
|
Others
|
|
Indocyanine green (Standard) is the analytical standard of Indocyanine green. This product is intended for research and analytical applications. Indocyanine green (Foxgreen) is a low toxicic fluorescent agent that has been widely used in medical diagnostics, such as determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography .
|
-
-
- HY-N6020BR
-
|
|
Others
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Butin is a major biologically active flavonoid isolated from the heartwood of Dalbergia odorifera with oral activity, with strong antioxidant, antiplatelet and anti-inflammatory activities. Butin significantly alleviates myocardial infarction and improves heart function, together with prevents diabetes-induced cardiac oxidative damage in rat .
|
-
-
- HY-P5319
-
|
|
Others
Calcium Channel
|
Others
|
|
MCaE12A is a high-affinity modulator of RyR2 and increases RyR2 sensitivity to cytoplasmic calcium concentrations promoting channel opening. MCaE12A acts as an important tool for RyR2 structure-to-function studies as well as for manipulating Ca2+ homeostasis and dynamic of cardiac cell .
|
-
-
- HY-B0252
-
|
HCTZ
|
TGF-beta/Smad
Potassium Channel
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
- HY-N0633
-
-
- HY-D0711S2
-
|
Foxgreen-d7; IC Green-d7; Cardiogreen-d7
|
Isotope-Labeled Compounds
Fluorescent Dye
|
Others
|
|
Indocyanine green-d7 (Foxgreen-d7) is the deuterium labeled Indocyanine green (HY-D0711). Indocyanine green is a low toxicic fluorescent agent that has been widely used in medical diagnostics, such as determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography .
|
-
- HY-19216
-
|
SKP 450
|
Potassium Channel
|
Cardiovascular Disease
|
|
KR-30450 (SKP 450) is a potent K +ATP opener, and a potassium channel activator. KR-30450 exerts more potent cardioprotective effects than Lemakalim (HY-14255). KR-30450 significantly improves reperfusion cardiac function. KR-30450 significantly attenuates reperfusion contracture and lactate dehydrogenase release .
|
-
- HY-14252A
-
|
Win 47203 lactate
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
Milrinone lactate is a potent inotropic dilating agent. Milrinone lactate shows simultaneous positive inotropic and vasodilating activities. Milrinone lactate promotes reduction of SVR and PVR in patients with DCM and NYHA class III and IV of heart failure. Milrinone lactate has the potential for the research of cardiovascular function after cardiac surgery and in septic shock .
|
-
- HY-B0252S
-
|
HCTZ-d2
|
TGF-beta/Smad
Potassium Channel
|
Cardiovascular Disease
Metabolic Disease
|
|
Hydrochlorothiazid-d2 is the deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
- HY-N0633R
-
-
- HY-B0252R
-
|
HCTZ (Standard)
|
Reference Standards
TGF-beta/Smad
Potassium Channel
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Hydrochlorothiazide (Standard) is the analytical standard of Hydrochlorothiazide. This product is intended for research and analytical applications. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
- HY-B0252S2
-
|
HCTZ-13C6
|
TGF-beta/Smad
Potassium Channel
|
Metabolic Disease
|
|
Hydrochlorothiazide- 13C6 is the 13C labeled Hydrochlorothiazide . Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
- HY-118960A
-
|
|
ATP Synthase
|
Cardiovascular Disease
|
|
BMS-199264 is an inhibitor of F1F0 ATP hydrolase (IC50=0.5 μM) without inhibitory effect on F1F0 ATP synthase. BMS-199264 selectively inhibits ATP decline during ischemia to reduces cardiac necrosis. BMS-199264 also enhances the recovery of contractile function following reperfusion .
|
-
- HY-118960
-
|
|
ATP Synthase
|
Cardiovascular Disease
|
|
BMS-199264 hydrochloride is an inhibitor of F1F0 ATP hydrolase (IC50=0.5 μM) without inhibitory effect on F1F0 ATP synthase. BMS-199264 hydrochloride selectively inhibits ATP decline during ischemia to reduces cardiac necrosis. BMS-199264 hydrochloride also enhances the recovery of contractile function following reperfusion .
|
-
- HY-B0252S1
-
|
HCTZ-13C,d2
|
Isotope-Labeled Compounds
TGF-beta/Smad
Potassium Channel
|
Cardiovascular Disease
Metabolic Disease
|
|
Hydrochlorothiazid- 13C,d2 is the 13C- and deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
- HY-173572
-
|
|
Sirtuin
Autophagy
|
Cardiovascular Disease
|
|
SKLB-11A is a selective, orally active and allosteric SIRT3 (sirtuin 3) agonist with a Kd value of 4.7 μM. SKLB-11A is highly selective for other members of the SIRT family. SKLB-11A activates autophagy-related signaling pathways, prevents mitochondrial dysfunction, improves cardiac function in Doxorubicin (HY-15142A)-induced cardiotoxicity and myocardial ischemia/reperfusion models .
|
-
- HY-101390B
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
Niguldipine free base is a calcium channel blocker with activity in regulating cardiovascular function. Niguldipine free base can reduce systolic and diastolic blood pressure, thereby increasing heart rate and cardiac output. Niguldipine free base exhibits dose-dependent and sustained increases in coronary blood flow. Niguldipine free base also increases perfusion in the kidneys and femoral arteries, but the effect is temporary and to a lesser extent. The effect of Niguldipine free base on myocardial metabolism is not significant .
|
-
- HY-145284
-
|
|
Apelin Receptor (APJ)
|
Cardiovascular Disease
|
|
APJ receptor agonist 4 is a potent and orally active agonist of apelin receptor (APJ) with EC50 and Ki of 0.06 nM and 0.07 nM respectively. APJ receptor agonist 4 displays excellent pharmacokinetic profiles in the rodent heart failure (HF) model. APJ receptor agonist 4 also shows an acceptable safety profile in preclinical toxicology studies. APJ receptor agonist 4 leads to improved cardiac function and can be used for researching the HF disease .
|
-
- HY-B0252S3
-
|
HCTZ-15N2,13C,d2
|
Potassium Channel
TGF-beta/Smad
Isotope-Labeled Compounds
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Hydrochlorothiazide- 15N2, 13C,d2 is 15N and deuterated labeled Hydrochlorothiazide (HY-B0252). Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
- HY-143248
-
|
|
G Protein-coupled Receptor Kinase (GRK)
HDAC
|
Cardiovascular Disease
|
|
KR-39038 is an orally active and potent GRK5 (G protein-coupled receptor kinase 5) inhibitor, with an IC50 of 0.02 μM. KR-39038 significantly inhibits angiotensin II-induced cellular hypertrophy through suppression of HDAC5 pathway in neonatal cardiomyocytes. KR-39038 shows profound anti-hypertrophic effects and improved cardiac function. KR-39038 can be used for heart failure research .
|
-
- HY-121705
-
-
- HY-P1723
-
Spexin
1 Publications Verification
Neuropeptide Q
|
Neuropeptide Y Receptor
Apoptosis
Ferroptosis
Autophagy
|
Cardiovascular Disease
Neurological Disease
|
|
Spexin (Neuropeptide Q) is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin can function through both central and peripheral actions. Spexin upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy .
|
-
- HY-P1723A
-
|
Neuropeptide Q TFA
|
Neuropeptide Y Receptor
Apoptosis
Ferroptosis
Autophagy
|
Cardiovascular Disease
Metabolic Disease
|
|
Spexin (Neuropeptide Q) TFA is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin TFA can function through both central and peripheral actions. Spexin TFA upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin TFA improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin TFA can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy .
|
-
- HY-175746
-
|
|
CX3CR1
|
Cardiovascular Disease
|
|
AZD0233 is an orally active CX3CR1 antagonist. AZD0233 modulates the CX3CR1/CX3CL1 signaling axis via immunomodulatory effects. AZD0233 has improved physicochemical properties, metabolic stability, low toxicity and CYP inhibition. AZD0233 improves cardiac function and reduces macrophages and fibrotic scar in mice model of dilated cardiomyopathy. AZD0233 can be used for cardiovascular diseases like dilated cardiomyopathy research .
|
-
- HY-19867A
-
|
TG-0054 hydrobromide
|
CXCR
VEGFR
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Burixafor (TG-0054) hydrobromide is a selective, orally active CXCR4 antagonist that effectively blocks the interaction between CXCR4 and its ligand, stromal cell-derived factor SDF-1. Burixafor hydrobromide interferes with the SDF-1/CXCR4 signaling pathway, prompting the release of bone marrow stem cells into the peripheral circulation, exerting immunomodulatory and anti-inflammatory activities. Burixafor hydrobromide can be used in the study of cancer, Intraocular neovascular diseases (such as choroidal neovascularization), myocardial infarction and other diseases, with the potential to mobilize stem cells, improve cardiac function and reduce inflammatory responses .
|
-
- HY-119038
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
ML-7 is a myosin light chain kinase inhibitor with the activity to inhibit superoxide anion (O(2)(-)) release in human neutrophils. ML-7 can affect the activity of neutrophils independently of myosin light chain kinase. ML-7 inhibits the extracellular O(2)(-) release of stimulated cells, but has no effect on the intracellular O(2)(-) production. ML-7 also strongly inhibits the binding of the intracellular compartment of oxide production to the cell membrane, indicating that it plays a key role in stimulated neutrophils. At the same time, ML-7 protects cardiac function from ischemia/reperfusion injury .
|
-
- HY-174400
-
|
|
SGLT
SOD
Na+/H+ Exchanger (NHE)
Autophagy
|
Cardiovascular Disease
|
|
SGLT2-IN-2 (Compound E9) is an inhibitor of SGLT2. SGLT2-IN-2 significantly enhances the inhibition of SGLT2, NHE1, and SOD enzyme activity. SGLT2-IN-2 has protective effect on the glucose-free DMEM-induced injured cardiomyocytes. SGLT2-IN-2 significantly improves cardiac function in TAC-induced HF mice and inhibits cardiomyocyte hypertrophy as well as collagen deposition. SGLT2-IN-2 can ameliorate myocardial tissue damage and enhance mitochondrial autophagy in injured cardiomyocytes, thereby increasing survival rates in HF mice .
|
-
- HY-158426
-
2-APQC
1 Publications Verification
|
Sirtuin
|
Cardiovascular Disease
|
|
2-APQC is an orally active and selective agonist of Sirtuin-3 (SIRT3) (Kd=2.756 μM), antagonizes Isoproterenol/ISO (HY-B0468)-induced cytotoxicity. 2-APQC activates the SIRT3-PYCR1 axis to enhance mitochondrial proline metabolism and inhibit the ROS-p38MAPK pathway by inhibiting signaling pathways such as mTOR-p70S6K, JNK, and TGF-β/Smad3. 2-APQC also activates the AMPK-Parkin axis to alleviate myocardial hypertrophy and fibrosis and protect cardiac function. 2-APQC can be used in the study of heart failure .
|
-
- HY-156193
-
|
|
PDHK
|
Cardiovascular Disease
Metabolic Disease
|
|
PF-07208254 is a selective, orally active allosteric inhibitor of branched-chain ketoacid dehydrogenase kinase (BDK) (IC50=110 nM, Ki=54 nM, KD=84 nM). PF-07208254 inhibits BDK-mediated BCKDH phosphorylation and enhances the catabolism of branched-chain amino acids (BCAAs) and branched-chain keto acids (BCKAs) by binding to the allosteric pocket of BDK, reducing BDK binding to BCKDH-E2 and promoting BDK degradation. PF-07208254 inhibits BDK activity in human skeletal muscle cells (IC50=540 nM) and has activity to improve cardiac function and metabolism. PF-07208254 can be used in the study of cardiometabolic diseases (e.g., heart failure, type 2 diabetes) .
|
-
- HY-159834
-
|
SLC-D011
|
DNA/RNA Synthesis
|
Others
|
|
Progerinin (SLC-D011) is an orally active progerin-lamin A binding inhibitor. Progerinin selectively binds to the C-terminal region of progerin, disrupting its interaction with lamin A and promoting progerin degradation while sparing wild-type lamin A, B, and C. Progerinin ameliorates nuclear deformation, increases H3K9me3 levels, and reduces progerin expression in HGPS patient-derived fibroblasts. Progerinin extends lifespan in Lmna G609G/G609G mice and Lmna G609G/+ mice, improves body weight, hair morphology, cardiac function, and histological phenotypes. Progerinin can be used for the study of Hutchinson-Gilford progeria syndrome (HGPS) .
|
-
- HY-13687A
-
|
|
IKK
LRRK2
P-glycoprotein
PKD
NF-κB
TNF Receptor
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
|
|
IKK 16 hydrochloride is an orally active IKK inhibitor. IKK 16 hydrochloride shows IC50s of 40 nM, 70 nM, 200 nM, and 50 nM for IKK2, IKK complex, IKK1, and LRRK 2, respectively. IKK 16 hydrochloride is also a pan-PKD inhibitor, inhibiting PKD1, PKD2, and PKD3 with IC50s of 153.9, 115, and 99.7 nM, respectively. IKK 16 hydrochloride is also an ABCB1 inhibitor, interfering with the binding of ABCB1 to its substrates. IKK 16 hydrochloride protects against LPS (HY-D1056)-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure. IKK 16 hydrochloride can restore renal function and alleviate fibrosis in acute kidney injury. IKK 16 hydrochloride attenuates cardiac dysfunction associated with polymicrobial sepsis in mice with type 2 diabetes mellitus (T2DM) by inhibiting the NF-κB pathway .
|
-
- HY-13687
-
|
|
IKK
LRRK2
P-glycoprotein
PKD
NF-κB
TNF Receptor
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
|
|
IKK 16 is an orally active IKK inhibitor. IKK 16 shows IC50s of 40 nM, 70 nM, 200 nM, and 50 nM for IKK2, IKK complex, IKK1, and LRRK 2, respectively. IKK 16 is also a pan-PKD inhibitor, inhibiting PKD1, PKD2, and PKD3 with IC50s of 153.9, 115, and 99.7 nM, respectively. IKK 16 is also an ABCB1 inhibitor, interfering with the binding of ABCB1 to its substrates. IKK 16 protects against LPS (HY-D1056)-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure. IKK 16 can restore renal function and alleviate fibrosis in acute kidney injury. IKK 16 attenuates cardiac dysfunction associated with polymicrobial sepsis in mice with type 2 diabetes mellitus (T2DM) by inhibiting the NF-κB pathway .
|
-
- HY-13687R
-
|
|
IKK
LRRK2
Reference Standards
P-glycoprotein
PKD
NF-κB
TNF Receptor
Interleukin Related
|
Inflammation/Immunology
|
|
IKK 16 (Standard) is the analytical standard of IKK 16. This product is intended for research and analytical applications. IKK 16 hydrochloride is an orally active IKK inhibitor. IKK 16 hydrochloride shows IC50s of 40 nM, 70 nM, 200 nM, and 50 nM for IKK2, IKK complex, IKK1, and LRRK 2, respectively. IKK 16 hydrochloride is also a pan-PKD inhibitor, inhibiting PKD1, PKD2, and PKD3 with IC50s of 153.9, 115, and 99.7 nM, respectively. IKK 16 hydrochloride is also an ABCB1 inhibitor, interfering with the binding of ABCB1 to its substrates. IKK 16 hydrochloride protects against LPS (HY-D1056)-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure. IKK 16 hydrochloride can restore renal function and alleviate fibrosis in acute kidney injury. IKK 16 hydrochloride attenuates cardiac dysfunction associated with polymicrobial sepsis in mice with type 2 diabetes mellitus (T2DM) by inhibiting the NF-κB pathway.
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D0711
-
|
Foxgreen; IC Green; Cardiogreen
|
Chromogenic Assays
|
|
Indocyanine green (Foxgreen) is a low toxicic fluorescent agent that has been widely used in medical diagnostics, such as determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography (Ex/Em = 785/813 nm) .
|
-
- HY-D0711R
-
|
|
Chromogenic Assays
|
|
Indocyanine green (Standard) is the analytical standard of Indocyanine green. This product is intended for research and analytical applications. Indocyanine green (Foxgreen) is a low toxicic fluorescent agent that has been widely used in medical diagnostics, such as determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1271A
-
|
|
nAChR
|
Cardiovascular Disease
|
|
Catestatin TFA is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin TFA is an endogenous peptide that regulates cardiac function and blood pressure . Catestatin TFA is a non-competitive nicotinic antagonist acting through nicotinic acetylcholine receptors (nAChRs) to inhibit catecholamine release .
|
-
- HY-P1373
-
|
|
Somatostatin Receptor
|
Neurological Disease
|
|
Neuronostatin-13 human is a 13-amino acid peptide hormone encoded by the somatostatin gene and plays an important role in the regulation of hormonal and cardiac function.
|
-
- HY-121705
-
-
- HY-P1723
-
Spexin
1 Publications Verification
Neuropeptide Q
|
Neuropeptide Y Receptor
Apoptosis
Ferroptosis
Autophagy
|
Cardiovascular Disease
Neurological Disease
|
|
Spexin (Neuropeptide Q) is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin can function through both central and peripheral actions. Spexin upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy .
|
-
- HY-P1271
-
|
Catestatin (cattle)
|
nAChR
|
Cardiovascular Disease
|
|
Catestatin is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin is an endogenous peptide that regulates cardiac function and blood pressure . Catestatin is a non-competitive nicotinic antagonist acting through nicotinic acetylcholine receptors (nAChRs) to inhibit catecholamine release .
|
-
- HY-P10336
-
|
|
Serpin
|
Neurological Disease
Endocrinology
|
|
Serpinin is an agonist of the protease inhibitor Nexin-1 (PN-1). Serpinin upregulates the expression of PN-1 through the cAMP-PKA-Sp1 signaling pathway, promoting granule biogenesis in endocrine cells. Serpinin is used in research related to the regulation of secretory function . Serpinin is a selective agonist for β-adrenergic receptors. Serpinin interacts with β1-adrenergic receptors to activate the AC-cAMP-PKA pathway, which regulates myocardial systolic and diastolic function. pGlu-serpinin upregulates Bcl2 mRNA transcription and exerts neuroprotective effects .
|
-
- HY-P1428A
-
|
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
|
|
RFRP-1(human) TFA is a potent endogenous NPFF receptor agonist (EC50 values are 0.0011 and 29 nM for NPFF2 and NPFF1, respectively). Attenuates contractile function of isolated rat and rabbit cardiac myocytes. Reduces heart rate, stroke volume, ejection fraction and cardiac output, and increases plasma prolactin levels in rats.
|
-
- HY-P5319
-
|
|
Peptides
Calcium Channel
|
Others
|
|
MCaE12A is a high-affinity modulator of RyR2 and increases RyR2 sensitivity to cytoplasmic calcium concentrations promoting channel opening. MCaE12A acts as an important tool for RyR2 structure-to-function studies as well as for manipulating Ca2+ homeostasis and dynamic of cardiac cell .
|
-
- HY-P1723A
-
|
Neuropeptide Q TFA
|
Neuropeptide Y Receptor
Apoptosis
Ferroptosis
Autophagy
|
Cardiovascular Disease
Metabolic Disease
|
|
Spexin (Neuropeptide Q) TFA is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin TFA can function through both central and peripheral actions. Spexin TFA upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin TFA improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin TFA can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0252S
-
|
|
|
Hydrochlorothiazid-d2 is the deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
-
- HY-B0252S2
-
|
|
|
Hydrochlorothiazide- 13C6 is the 13C labeled Hydrochlorothiazide . Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
-
- HY-109128S
-
|
|
|
Danicamtiv-d6 (MYK-491-d6) is a deuterated labeled Danicamtiv (HY-109128). Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency .
|
-
-
- HY-109128S1
-
|
|
|
Danicamtiv-d3 (MYK-491-d3) is a deuterated labeled Danicamtiv (HY-109128). Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency .
|
-
-
- HY-109128S2
-
|
|
|
Danicamtiv-d3-1 (MYK-491-d3-1) is a deuterated labeled Danicamtiv (HY-109128). Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency .
|
-
-
- HY-B1409S
-
|
|
|
Isosorbide dinitrate- 13C6 is the 13C labeled Isosorbide dinitrate . Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI) .
|
-
-
- HY-B0124S2
-
|
|
|
Zonisamide- 13C6 (AD 810- 13C6) is 13C labeled Zonisamide. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
|
-
-
- HY-D0711S2
-
|
|
|
Indocyanine green-d7 (Foxgreen-d7) is the deuterium labeled Indocyanine green (HY-D0711). Indocyanine green is a low toxicic fluorescent agent that has been widely used in medical diagnostics, such as determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography .
|
-
-
- HY-B0252S1
-
|
|
|
Hydrochlorothiazid- 13C,d2 is the 13C- and deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
-
- HY-B0252S3
-
|
|
|
Hydrochlorothiazide- 15N2, 13C,d2 is 15N and deuterated labeled Hydrochlorothiazide (HY-B0252). Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-174671
-
|
|
|
mRNA
|
|
Human HBEGF mRNA encodes the human heparin binding EGF like growth factor (HBEGF) protein, a growth factor that mediates its effects via EGFR, ERBB2 and ERBB4. HBEGF may be involved in normal cardiac valve formation and normal heart function.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
